Kornimate/medical-research-clean huggingface dataset:
gene expression outcomes in interventions for substance using hiv+ minority men

Conditions: Human Immunodeficiency Virus Infection; Inflammation

Summary: this is a pilot study of a new 9-session individually delivered cognitive behavioral intervention targeting sexual minority stress. in this study, 40 hiv+ men sexual minority men will be recruited for the study then will be randomly assigned to either the new 9 session intervention or a writing task condition.


Eligibility criteria:
inclusion criteria: * provide evidence or documentation of hiv positive status (e.g. a letter of diagnosis or medication bottles with matched photo id) * be english speaking * be able to consent * sexual activity with a man in the 3 years prior to initial contact or identification as gay or bisexual * not currently be enrolled in formal substance abuse treatment * report at least one occasion of drinking 5 or more drinks or of using an illicit substance in the previous 3 months, but not meet criteria for a severe substance use disorder. exclusion criteria: * presence of a severe substance use disorder * presence of current symptoms consistent with schizophrenia or bipolar disorder, which would indicate that an intervention targeting these symptoms would be more appropriate.
delta shock index in predicting massive transfusion

Conditions: Trauma Patients Received Blood Transfusion ≥ 10 U; Trauma Patients Had Not Received Blood Transfusion ≥ 10 U

Summary: background: to determine the performance of delta shock index (δsi), a change in shock index (si) upon arrival at the emergency room (er) from that in the field in predicting the need for massive transfusion (mt) among adult trauma patients with stable blood pressure. methods: this study included data from all trauma patients aged 20 years and above who were hospitalized from january 1, 2009 to december 31, 2016 and was obtained from the registered trauma database of the hospital. only patients who were transferred by emergency medical service from the accident site with a systolic blood pressure ≥ 90 mm hg at the er were included in this study. the 7,957 enrolled trauma patients were divided into 2 groups, those who had received blood transfusion ≥ 10 u (mt, n = 82) and those who had not (non-mt, n = 7,875). the odds ratios with 95% confidence intervals for associated patient conditions and the odds of need for mt by a given δsi were measured. the plot of specific receiver operating characteristic (roc) curves was used to evaluate the best cutoff point that could predict the patient's probability of receiving mt.


Eligibility criteria:
inclusion criteria: * patients who were transferred by emergency medical service (ems) from the field of accident and had a stable blood pressure (sbp ≥ 90 mmhg) at the er were included exclusion criteria: * patients who were transferred from other hospitals or arrived by private vehicles. * patients who had incomplete data * patients who had an unstable blood pressure (sbp \< 90 mmhg) upon arrival at the er were also excluded
ligamentum teres tenodesis in developmental dysplasia of the hip

Conditions: Orthopedic Disorder

Summary: the treatment of developmental dysplasia of the hip (ddh) remains challenging, yet recent advances have refined our understanding of how best to survey for the condition during infancy, minimize complications during early treatment, and refine the selection of patients who can best benefit from hip preservation surgery. the ideal continued target would be to prevent missed hip dislocations or dysplasia during the infant period, prevent avascular necrosis (avn) during early treatment, and decrease the incidence of total hip arthroplasty in adulthood related to undertreated ddh, the goal of the treatment is to achieve a concentric reduction of the femoral head into the acetabulum.

it is an operative technique to secure the femoral head after reduction in cases of developmental dysplasia of the hip operative technique: the surgery will be accomplished under a general anesthesia. an addition to the steps of the open reduction, the following were done: 1. identification of ligamentum teres 2. ligamentum teres tenodesis

Eligibility criteria:
inclusion criteria: * patient with developmental dysplasia of the hip (ddh) with : * age: from 9 months -5 years old. * virgin ddh. * failed closed reduction in the management of ddh. * failed open reduction through medial approach in the management of ddh exclusion criteria: * • paralytic hip dislocation . * post septic hip dislocation. * traumatic hip dislocation . * age : below 9 months or above 5 years. * refusal to participate in this study.
lifestyle-modifying interventions in low-risk mds patients

Conditions: Myelodysplastic Syndromes

Summary: myelodysplastic syndromes (mds) are acquired clonal stem cell diseases characterized by hematopoietic cell dysplasia, cytopenia, and the risk of progression to acute myeloid leukemia. in addition to clonal changes in the hematopoietic stem and progenitor cells itself, growing evidence suggests that inflammatory and metabolic changes in the bone marrow microenvironment play an important role in disease development and maintenance of the malignant clone. the positive impact of dietary interventions (e.g. fasting) and physical activity on inflammation and metabolic parameters could be shown in various benign inflammatory disease entities (e.g. atherosclerosis, chronic renal insufficiency, cystic fibrosis etc.). the aim of this study is to describe the hematological, metabolic, inflammatory, and microbiological changes after combined lifestyle-modifying interventions (outpatient physiotherapy and fasting mimicking diet (fmd) in patients with low-risk mds.


Eligibility criteria:
inclusion criteria: 1. 18-75 years of age 2. cytomorphologically confirmed mds or mds/mpn according to who criteria (incl. mds-rars-t, cmml) 3. ipss-r very low, low, or intermediate 4. hemoglobin \<11 g/dl (6.8 mmol/l) 5. non-transfusion dependent (ntd) per iwg 2018 criteria (≤2 blood transfusions within 16 weeks prior to inclusion in the study) 6. ecog≤2 7. body mass index (bmi) ≥ 20 kg/m2 8. written informed consent of the subject after clarification exclusion criteria: 1. aml 2. mds ipss-r high or very high 3. history of hsct 4. mds-specific drug therapy (including erythropoietin, erythropoiesis-modulating agents, lenalidomide, iron chelation, hypomethylating agents) ongoing or planned in the next 6 months 5. diabetes mellitus requiring therapy or any other known metabolic disease 6. application of systemic cortisone-containing drugs 7. known psychiatric eating disorder (e.g. anorexia nervosa, bulimia) 8. physical inability to follow the physical and/or nutritive interventions 9. simultaneous participation in another interventional clinical trial (including within the last 4 weeks before inclusion) 10. addictions or other illnesses that do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences 11. pregnant or breastfeeding women 12. indications that the subject is unlikely to adhere to the protocol (e.g., lack of compliance)

Keywords: myelodysplastic syndrome fasting-mimicking diet physiotherapy lifestyle modification inflammation metabolism
a study to assess the safety, tolerability, and efficacy of imvt-1402 in participants with cutaneous lupus erythematosus (cle)

Conditions: Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus

Summary: the primary purpose of this study is to evaluate the efficacy, safety, and tolerability of imvt-1402 in participants with cutaneous lupus erythematosus. the study will consist of 3 periods: period 1: eligible participants will be randomized 1:1 to imvt-1402 or placebo sc qw for 12 weeks. period 2: participants who completed period 1 will receive imvt-1402 sc qw for 14 weeks. period 3: after completion of period 2, participants will be re-randomized 1:1 to blinded imvt-1402 sc qw for 26 weeks.

the total study duration per participant is up to 67 weeks.

Eligibility criteria:
inclusion criteria: * have documented diagnosis of scle or ccle that has been confirmed by biopsy with or without systemic le manifestations. * have a total clasi-a score of ≥10 at screening and day 1. participants with a clasi-a score of ≥8 and \<10 are eligible if the score does not include alopecia and/or mucous membrane lesions. * have active cle despite an adequate trial of conventional therapies. * are positive for at least one of the following as assessed at screening. exclusion criteria: * have known or suspected drug-induced cle anti-phospholipid disease, or neuropsychiatric sle. * have rapidly progressive nephritis. * have current inflammatory skin disease other than scle/ccle that, in the opinion of the investigator, could interfere with the inflammatory skin assessments or confound the disease activity assessments. note: other protocol defined inclusion/exclusion criteria may apply

Keywords: chronic cutaneous lupus erythematosus subacute cutaneous lupus erythematosus imvt-1402
topical analgesia post-haemorrhoidectomy

Conditions: Hemorrhoid Pain; Hemorrhoids

Summary: symptomatic haemorrhoids, or piles, have significant effects on quality of life. the treatment for advanced disease is surgical excision (haemorrhoidectomy) which is extremely effective. however, pain following haemorrhoidectomy is known by all to be a miserable experience and current treatment is not very effective. we have formulated a new cream treatment which targets three theorised mechanisms of pain after haemorrhoidectomy. we will test the effectiveness of the treatments with a multi-centred randomised controlled factorial trial with four parallel double-blinded arms containing different combinations of the active agents. the outcomes include pain scores, amount of analgesia required and time to return to work. the results of our study could provide evidence of an effective treatment for post haemorrhoidectomy pain. the treatment may provide considerable benefit to patients undergoing this surgical procedure.

study design: this will be a patient-and-investigator blinded factorial randomised trial with four parallel groups. participants in all four groups will be instructed to apply cream 3 times a day for 7 days after surgery. a standard analgesia prescription will be provided with laxatives as per routine care. patients will be provided a questionnaire to complete and return on day 14. random sequence generation: computer generated sequence allocating patients to a 1:1:1:1 ratio using permuted block randomisation in blocks of 12. allocation concealment: this randomisation code will be seeded to the pharmacist to who will package and label the cream according to a code. the creams will be indistinguishable to which active ingredient they contain. assignment of intervention: patients will be assigned in order according to the numbering of the cream tubes by the blinded investigator. data recording: data will be recorded on redcap database.

Eligibility criteria:
inclusion criteria: * age ≥16 * all patients undergoing excisional haemorrhoidectomy exclusion criteria: * age \<16, * history of chronic pain, * drug allergy or idiosyncracies to any actives or excipients in * cream, * breastfeeding, * any medical history which is a contraindication to any of metronidazole, lidocaine, or diltiazem including including: * sick sinus syndrome, * atrioventricular block, * hypotension, * heart failure and bradycardia. * concomitant medications which are contraindicated to metronidazole, lidocaine or diltiazem. * patients already taking diltiazem.
a single center experience in the management of pilonidal disease

Conditions: Pilonidal Sinus

Summary: sacrococcygeal pilonidal disease (pnd) is a common entity affecting the skin and subcutaneous tissue of the upper portion of the natal cleft of the buttocks. it is characterized by the presence of sinus tracts with recurrent inflammation and infection. it poses a significant healthcare problem due to its related morbidity, impaired quality of life, and financial costs.

this acquired disease is caused by negative suction of the hair present in the natal cleft region, leading to a foreign body reaction and subsequent granuloma . it affects 26 per 100000 people, and it mainly affects young men . surgery for pnd is frequently performed in egypt by general surgeons, with no published data regarding its incidence or prevalence in the egyptian population. the pnd patient may report different presentations ranging from asymptomatic disease to acute infection and abscess formation. others may have a chronic disease with recurrent perianal inflammation and discharge. multiple surgical options have been described for chronic pnd. however, no technique has been universally accepted. the idea of any procedure is to excise the pits with the related sinus tracts leaving healthy tissue as possible to decrease recurrence. the most commonly performed surgical techniques include excision with either primary closure, lay open, or flap-based reconstruction.

Eligibility criteria:
inclusion criteria: * both sexes * aging between 18- 60 years old * who underwent surgical intervention for the pilonidal sinus (either primary or recurrent) * the surgical intervention includes excision with primary closure or lay open technique, rhomboid flap and rotational flap. exclusion criteria: * surgically unfit due to commodities. * those who lost follow up

Keywords: sacrococcygeal pilonidal sinus primary closure limberg flap rotational flap
ultrasound-guided prp versus steroid injections in management of carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: patients will be randomly divided into 3 equal groups: group i received ultrasound guided injection of 2 ml prp into the affected carpal tunnel. group ii received ultrasound guided injection of 2 ml steroids (40 mg triamcinolone acetonide). group iii received ultrasound guided injection of 2 ml saline as placebo control.

patients will be randomly divided into 3 equal groups: group i received ultrasound guided injection of 2 ml prp into the affected carpal tunnel. group ii received ultrasound guided injection of 2 ml steroids (40 mg triamcinolone acetonide). group iii received ultrasound guided injection of 2 ml saline as placebo control. each group will be injected twice with 2 weeks intervals. all procedures were done after informed consent. evaluation of the patients at baseline, 3 and 6 months after last injection was done clinically by measuring visual analogue scale (vas), electrophysiologically (by measuring motor and sensory nerve conduction studies of median nerve using a standardized technique) and ultrasonographic study by measuring cross sectional area (csa) of median nerve at the level of pisiform.

Eligibility criteria:
inclusion criteria: * mild or moderate idiopathic cts (diagnosed clinically, ultrasonography \& electrophysiologically and classified according to the american association of neuromuscular diagnostic medicine monograph). exclusion criteria: * patients with severe or secondary type of cts

Keywords: prp injection local injection cts
wearable device for motivating hand use after stroke

Conditions: Cerebral Stroke

Summary: the goal of this study is to determine the effectiveness of interactive feedback from a wearable device that senses hand function, the manumeter, in improving upper extremity function in a pilot, randomized controlled trial with chronic stroke patients

in this randomized controlled trial, the investigators will compare two groups of chronic stroke participants group 1 of study participants will use the manumeter with interactive functions to monitor and motivate upper extremity functional activity. group 2 of study participants will use the manumeter but receive no feedback and will be given the current standard-of-care, a booklet describing a home exercise program for increasing upper extremity exercise. the investigators hypothesize that study participants who interactively monitor functional activity with the manumeter will improve their upper extremity function significantly more.

Eligibility criteria:
inclusion criteria: * 18 to 80 years of age * experienced one or multiple strokes at least six months previously * upper extremity fugl-meyer score \< 60 out of 66 * absence of moderate to severe upper limb pain (\< 3 on the a 10 point visual-analog pain scale) * ability to understand the instructions to operate the device exclusion criteria: * 80 years of age and above * implanted pacemaker * moderate to severe pain in affected arm * severe tone in affected arm as measured on a standard clinical scale * language problem that would prevent from properly understanding instructions * currently pregnant * difficulty in understanding or complying with the instructions given by the experimenter * inability to perform the experimental task that will be studied
a study to evaluate the tolerance and pharmacokinetics of tqb3720 tablets

Conditions: Metastatic Castration-resistant Prostate Cancer

Summary: this study is conducted to investigate the pharmacokinetic and safety profiles of tqb3720 in patients with metastatic castration-resistant prostate cancer.


Eligibility criteria:
inclusion criteria: * 1. histologically or cytologically confirmed prostate carcinoma. 2.eastern cooperative oncology group (ecog) performance status score of 0 to 2; life expectancy ≥12 weeks. 3.testosterone levels \< 50 ng/dl. 4. has received ≥1 previous regimens for metastatic castration-resistant prostate cancer. 5.male subjects should agree to use an adequate method of contraception starting with signing icf through 6 months after the last dose of study. 6.understood and signed an informed consent form. exclusion criteria: -1.has symptomatic brain metastases or control of symptoms \< 1 month. 2.has other malignancies within 3 years. 3.has used second-generation androgen receptor antagonists. 4. abnormal liver function. 5. abnormal renal function. 6. has received any other investigational drug within 30 days weeks before first dose. 7. according to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
counteracting age-related loss of skeletal muscle mass (calm)

Conditions: Sarcopenia; Muscle Loss

Summary: up to 66 healthy elderly individuals (at least 65 years old) are recruited as subjects. they will be recruited as a subgroup to protocol id: h-4-2013-070. upon inclusion, each individual will be randomized into one of the five groups stratified according to gender (m/f) and 30s chair stand (\<16 or ≥16). the five groups are: heavy resistance training (n=12), light intensity training (n=12), protein whey (n=15), protein collagen (n=15) and carbohydrate (n=12). the individuals randomized into one of the supplementation groups (protein whey, protein collagen or carbohydrate) will be blinded to the supplement content. assessments will be performed at baseline (before intervention start) and after 12 months of intervention. the primary outcomes are measures of muscle protein synthesis rate measured as the fractional synthesis rate from baseline to 12 months of intervention. the hypotheses are i) that basal and protein-stimulated muscle protein synthesis rates are elevated in the exercise training groups after 12 months of intervention. ii) prolonged intake of protein of different quality will improve the muscle protein synthetic response to protein intake after 12 months of intervention.


Eligibility criteria:
inclusion criteria: * healthy, independently living * age at least 65 years exclusion criteria: * subjects dependent on help/nursing etc. * chronic medical diseases: diabetes mellitus, clinical knee or hip osteoarthritis, other types of arthritis or connective tissue disorders, active cancer, renal diseases, severe chronic obstructive pulmonary disease, cardiac arrhythmias or known decreased left ventricular ejection fraction, lactose or gluten intolerance, chronic inflammatory bowel diseases, non-treated hyper/hypothyroidism, dementia * surgical diseases: bone, muscle, tendon or joint injuries compromising participation in exercise regimens * implanted magnetic devices incompatible with mri-scanning * weekly alcohol consumption \> 21 units (1 unit equals 4 g of ethanol) for men and \> 14 for women * medicine except acetylsalicylic acid, paracetamol, thyroid function hormones, statins in doses above 40 mg/day or if combined with subjective myalgia, ace-inhibitors, angiotensin ii blockers, beta-blockers, calciumantagonists, proton-pump inhibitors, thiazides, potassium-sparring diuretics and loop diuretics * 1 hour of exercise weekly, except light activities such as stretching/gymnastics and bike-riding/walking as transportation

Keywords: sarcopenia frailty ageing protein supplementation protein quality exercise training muscle protein turnover
effectiveness of virtual reality in patients with chronic neck pain

Conditions: Pain, Neck; Virtual Reality; Proprioception; Balance

Summary: virtual reality application has been increasing in recent years for pain control, distraction in wound care, treatment of anxiety disorders and support for physical rehabilitation. for example, it has been found to be effective in reducing pain when used in addition to medical treatment during bandaging of severe burns. the studies related with chronic pain patients were stated that virtual reality application was found to be interactive and fun by patients. therefore, the aim of this study was to investigate the effects of virtual reality on pain threshold, disability, balance, proprioception, exercise sustainability, muscular performance in neck region, quality of life and anxiety / depression in addition to the exercise program that includes stabilization exercises in patients with chronic neck pain.


Eligibility criteria:
inclusion criteria: * to have pain more than 3 months, * to be sedentary, * to have neck disability index score more than 10. exclusion criteria: * to have neurological deficits, vestibular pathology, history of surgery.

Keywords: neck pain virtual reality proprioception balance
safety and efficacy of vilazodone in major depressive disorder

Conditions: Major Depressive Disorder

Summary: safety and efficacy of vilazodone in major depressive disorder


Eligibility criteria:
inclusion criteria: * men and women, 18-70 years of age * currently meet the dsm-iv-tr criteria for major depressive disorder * the patient's current major depressive episode must be at least 8 weeks and no longer than 18 months in duration exclusion criteria: * women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control * patients with a history of meeting dsm-iv-tr criteria for: * any manic, hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic, or mixed episode; * any depressive episode with psychotic or catatonic features; * panic disorder with or without agoraphobia; * obsessive-compulsive disorder; * schizophrenia, schizoaffective, or other psychotic disorder; * bulimia or anorexia nervosa; * presence of borderline personality disorder or antisocial personality disorder; h. mental retardation, dementia, amnesia, or other cognitive disorders * patients who are considered a suicide risk

Keywords: major depressive disorder depression